Stock Price
113.20
Daily Change
-2.90 -2.50%
Monthly
-6.83%
Yearly
-71.48%
Q4 Forecast
109.66



Peers Price Chg Day Year Date
Evogene 113.20 -2.90 -2.50% -71.48% Nov/13
FutureFuel 2.90 0.07 2.47% -13.69% Nov/13
Globe Specialty Metals 3.00 -0.05 -1.64% -22.08% Nov/13
Hawkins 148.68 -1.69 -1.12% 17.51% Nov/13
Innospec 80.39 1.28 1.62% 8.50% Nov/13
Intrepid Potash 32.91 -0.43 -1.29% 25.61% Nov/13
Koppers 31.16 -0.54 -1.70% 7.67% Nov/13
Kronos Worldwide 8.29 -0.12 -1.43% 75.26% Nov/13
LSB Industries 11.43 -0.24 -2.06% 17.71% Nov/13
Materion 203.93 -4.23 -2.03% 75.20% Nov/13

Indexes Price Day Year Date
TA-125 3921 -38.61 -0.98% 11.84% Nov/13

Evogene traded at 113.20 this Friday November 13th, decreasing 2.90 or 2.50 percent since the previous trading session. Looking back, over the last four weeks, Evogene lost 6.83 percent. Over the last 12 months, its price fell by 71.48 percent. Looking ahead, we forecast Evogene to be priced at 109.66 by the end of this quarter and at 99.68 in one year, according to Trading Economics global macro models projections and analysts expectations.

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.